
June 26 (Reuters) - Edgewise Therapeutics Inc EWTX.O:
EDGEWISE THERAPEUTICS REPORTS POSITIVE RESULTS ON SEVASEMTEN PROGRAM FOR BECKER AND DUCHENNE MUSCULAR DYSTROPHIES
EDGEWISE THERAPEUTICS INC - TO MEET WITH FDA IN Q4 2025 TO DISCUSS PHASE 3 DESIGN
EDGEWISE THERAPEUTICS INC - NEW DATA SHOWS SUSTAINED DISEASE STABILIZATION IN BECKER UP TO THREE YEARS
EDGEWISE THERAPEUTICS INC - PHASE 2 OBSERVATIONS IN DUCHENNE DEFINE DOSE FOR PHASE 3